Sfoglia per AUTORE
CORRADINI P
Collezione AO Ordine Mauriziano

  

Items : 21

Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy. in Hematological oncology / Hematol Oncol. 2020 Oct;38(4):501-508. doi: 10.1002/hon.2775. Epub 2020 Jul 30.

2020
AO Ordine Mauriziano
AO Cuneo

Gallamini A; Gianni AM; Corradini P; Galbiati M; Ferreri AJM; Farina L; Zanotti R; Cimminiello M; Tarella C; Gottardi D; Guidetti A; Sorasio R; Trentin L; Romano A; Patti C; Rossi A; Taverna F; Pavoni C; Mazzocchi A; Viviani S; Rambaldi A;

Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2018 Feb 10;36(5):454-462. doi: 10.1200/JCO.2017.75.2543. Epub 2018 Jan 23.

2018
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino

Rambaldi A; Gianni AM; Pavoni C; Chauvie S; Bergesio F; Prosperini G; Chiaravalloti A; Gregianin M; Ficola U; Fallanca F; Biggi A; Avigdor A; Billio A; Miglino M; Viero P; Ferreri AJM; Gini G; Zanotti R; Parvis G; Schiavotto C; Cimminiello M; Corradini P; Gavarotti P; Gottardi D; Battistini R; Rapezzi D; Bolis S; Trentin L; La Nasa G; et alii...

Early chemotherapy intensification with escalated BEACOPP in advanced-stage Hodgkin lymphoma with a positive interim PET-CT after 2 ABVD cycles: Long-term results of the GITIL/FIL HD 0607 trial in Haematologica

2017
AO Ordine Mauriziano

Gallamini A; Rossi A; Patti K; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Viviani S; Gianni AM; Zoli V; Gottardi D; Tarella C; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJ; Viero P; Miglino M; Billio A; Avigdor A; Prosperini G; Bergesio F; et alii...

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980. Epub 2016 Oct 31.

2016
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano

Rambaldi A; Boschini C; Delaini F; Masciulli A; Pileri S; Tabanelli V; Bruna R; Chilosi M; Falorio S; Flenghi L; Frezzato M; Trentin L; Gini G; La Nasa G; Benedetti F; Ferreri AJ; Di Raimondo F; Castellino C; Negri G; Piccin A; Billio A; Zoli V; Zanni M; Mulé A; Corradini P; Patti C; Di Nicola M; Gritti G; Rossi A; et alii...

Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. in International journal of radiation oncology, biology, physics / Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):783-91. doi: 10.1016/j.ijrobp.2015.12.019. Epub 2015

2016
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L;

Sequential high-dose cytarabine plus idarubicin improves remission rate and survival duration in adult acute myelogenous leukemia (AML): Randomized trial of the Northern Italy leukemia group (NILG) in Haematologica

2016
AOU Alessandria
AO Ordine Mauriziano
AO Cuneo

Bassan R; Intermesoli T; Masciulli A; Boschini C; Gianfaldoni G; Marmont F; Cavattoni I; Mattei D; Terruzzi E; De Paoli L; Rossi G; Borlenghi E; Ciceri F; Bernardi M; Scattolin AM; Todisco E; Campiotti L; Corradini P; Cortelezzi A; Tajana M; Ferrero D; Cignetti A; Marfisi RM; Delaini F; Zanghì P; Oldani E; Spinelli O; Audisio E; Cortelazzo S; et alii...

Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. in Leukemia / Leukemia. 2014 Sep;28(9):1885-91. doi: 10.1038/leu.2014.79. Epub 2014 Feb 20.

2014
AO Ordine Mauriziano
AO Cuneo
AOU Alessandria

Pileri S; Dodero A; Tarella C; Ferreri A; Patti C; Baldini L; Bruno B; Salvi F; Todeschini G; Rossi G; Benedetti F; Olivieri A; Gallamini A; Patriarca F; Miceli R; Rambaldi A; Corradini P; Vitolo U;

Long-term results of the phase III GITMO/FIL trial of CHOP-R versus R-HDS plus autograft in high-risk follicular lymphoma (FL) at diagnosis in Journal of Clinical Oncology

2014
AO Ordine Mauriziano

Magni M; Ladetto M; Gueli A; Passera R; Bruna R; Corradini P; Zoli V; Perrone T; Stelitano C; Rossini F; Castellino C; Gini G; Liberati AM; Musso M; Pulsoni A; Barbui AM; Patti C; Boccomini C; Benedetti F; Tarella C;

Successful second autologous engraftment after long duration storage of hematopoietic stem cells in Bone Marrow Transplantation

2013
AO Ordine Mauriziano

Longoni P; Milanesi M; Di Nicola M; Devizzi L; Carrabba M; Arienti F; Ravagnani F; Tarella C; Montefusco V; Gianni A; Corradini P; Magni M;

Intensified program including bendamustine, high dose therapy and autograft for patients with relapsed or resistant follicular non hodgkin lymphoma: Results from an exploratory gitil study in Hematological Oncology

2013
AO Ordine Mauriziano

Patti C; Mule' A; Barbui A; Tringali S; Costa A; Gueli A; Castellino C; Magni M; Dodero A; Leone M; Fabbiano F; Gallamini A; Corradini P; Gianni A; Tarella C; Rambaldi A; Scime' R;

The lymphocytes to monocytes ratio identifies a patient subgroup among high risk DLBCL that may benefit from upfront intensive treatment with autograft in Haematologica

2013
AO Ordine Mauriziano

Barbui AM; Masciulli A; Scarano M; Delaini F; Rossi A; Ladetto M; Corradini P; Di Nicola M; Patty C; Mulè A; Zanni M; Zoli V; Billio A; Gallamini A; Di Raimondo F; Ferreri AJM; Benedetti F; Leoni P; Semenzato G; Frezzato M; Flenghi L; Marchioli R; Barbui T; Gianni AM; Tarella C; Cortelazzo S; Rambaldi A;

Intensified chemo-immunotherapy including up-front autologous or allogeneic stem cell transplantation (SCT) for young patients with newly diagnosed peripheral T-cell lymphomas: Final results of a phase II multicenter prospective clinical trial in Blood

2012
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Corradini P; Vitolo U; Rambaldi A; Miceli R; Patriarca F; Gallamini A; Olivieri A; Benedetti F; Todeschini G; Rossi G; Parvis G; Salvi F; Bruno B; Baldini L; Patti C; Milone G; Ferreri AJM; Tarella C; Pileri SA; Dodero A;

Safety, tolerability and activity of ofatumumab, bendamustine and dexamethasone combination as first-line treatment of mantle-cell lymphoma in the elderly: A multicenter study in Blood

2011
AO Ordine Mauriziano

Magni M; Di Nicola M; Carlo-Stella C; Devizzi L; Guidetti A; Matteucci P; Viviani S; Zambelli S; Ferreri AJM; Rambaldi A; Di Raimondo F; Tarella C; Gallamini A; Nobile F; Vallisa D; Carella AM; Patti C; Quarta G; Rizzoli V; Benedetti F; Corradini P; Gianni AM;

Comparative assessment of telomere length before and after hematopoietic SCT: Role of grafted cells in determining post-transplant telomere status in Bone Marrow Transplantation

2010
AO Ordine Mauriziano

Ruella M; Rocci A; Ricca I; Carniti C; Bodoni CL; Ladetto M; Caracciolo D; Boccadoro M; Carlo-Stella C; Corradini P; Tarella C;

Male gender, quality of grafted cells, advanced age, rituximab and radiotherapy are the main factors that variously influence the occurrence of secondary malignancies following high-dose therapy and autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) survey in 1,347 lymphoma patients in Blood

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Passera R; Magni M; Rossi A; Benedetti F; Gueli A; Patti C; Parvis G; Ciceri F; Gallamini A; Cortelazzo S; Corradini P; Zoli V; Mule A; Crocchiolo R; Bosa M; Barbui A; Di Nicola M; Caracciolo D; Sorio M; Gianni AM; Rambaldi A;

Dexamethasone, cytarabine and cisplatin or oxaliplatin schedule (DHAP or OX-DHA) is effective and widely applicable in chronic lymphocytic leukemia and waldenström macroglobulinemia in Blood

2009
AO Ordine Mauriziano

Ruella M; Ricca I; Gueli A; Gottardi D; Caracciolo D; Bergui L; Gavarotti P; De Crescenzo A; Farina L; Corradini P; Tarella C;

High response rate with favorable survival projections in high-risk patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP-14 or early intensified chemotherapy with rituximab and autograft (R-HDS): Results of the interim analysis of a gitil prospective multicenter phase III study in Blood

2009
AO Ordine Mauriziano

Cortelazzo S; Tarella C; Gianni AM; Ladetto M; Zanni M; Corradini P; Di Nicola M; Patti C; Mulè A; Majolino I; Billio A; Gueli A; Di Raimondo F; Chiarenza A; Gallamini A; Ferreri A; Pizzolo G; Benedetti F; La Nasa G; Leoni P; Gini G; Trentin L; Rodeghiero F; Marchioli R; Barbui T; Barbui A; Rambaldi A;

Preliminary results of a phase II trial with the multikinase inhibitor sorafenib in heavily pretreated patients with relapsed/refractory non-Hodgkin lymphoma (NHL) in Blood

2009
AO Ordine Mauriziano

Guidetti A; Carlo-Stella C; Devizzi L; Matteucci P; Marchianò A; Lanocita R; Magni M; Dodero A; Tarella C; Di Nicola M; Corradini P; Gianni AM;

The long-term outcome of high-risk follicular lymphoma patients receiving intensive therapy with autograft as primary treatment: Results from three consecutive prospective trials performed in Italy over the past 18 years in Haematologica

2009
AO Ordine Mauriziano

Corradini P; Gianni AM; Pileri A; Passera R; Ruella M; Ladetto M; Tarella C;

Factors influencing the occurrence of secondary myelodysplastic syndrome/acute leukemia following high-dose therapy and autograft: A GITIL (Gruppo Italiano Terapie innovative nei linfomi) survey in 1,347 lymphoma patients in Haematologica

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Passera R; Magni M; Rossi A; Gueli A; Benedetti F; Patti C; Parvis G; Ciceri F; Gallamini A; Cortelazzo S; Corradini P; Zoli V; Leone M; Bosa M; Barbui A; Di Nicola M; Boccadoro M; Sorio M; Gianni AM; Rambaldi A;

Histology and rituximab addition are the main factors influencing the long-term outcome in high-risk lymphoma following high-dose therapy and autograft: A 20-yr. Follow-up in 1,347 patients by gitil (gruppo italiano terapie innovative NEI Linfomi) in Haematologica

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Di Nicola M; Rossi A; Caracciolo D; Passera R; Benedetti F; Patti C; Parvis G; Ciceri F; Castellino C; Cortelazzo S; Corradini P; Majolino I; Mule' A; Bosa M; Barbui A; Magni M; Boccadoro M; Sorio M; Rambaldi A; Gianni AM;